Caspofungin as First-Line Therapy for the Treatment of Invasive Aspergillosis After Thoracic Organ Transplantation

Journal of Heart and Lung Transplantation

Volumn 27, Issue 1, 2008, Pages 1-6

  Groetzner, Jan ^a   Kaczmarek, Ingo ^b   Wittwer, Thorsten ^a   Strauch, Justus ^a   Meiser, Bruno ^b   Wahlers, Thorsten ^a   Daebritz, Sabine ^b   Reichart, Bruno ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIVER FAILURE; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MALE; NEUTROPENIA; PHLEBITIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SEROLOGY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, FUNGAL; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 37549037850     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.10.002     Document Type: Article

References (24)

1. Paterson D.L., and Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 78 (1999) 123-138
2. Cannon J.P., Garey K.W., and Danziger L.H. A prospective and retrospective analysis of nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 21 (2001) 1107-1114
3. Walsh T.J., Yeldandi V., McEvoy M., et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 42 (1998) 2391-2398
4. Denning D.W., Tucker R.M., Hanson L.H., and Stevens D.A. Itraconazole in opportunistic mycoses: cryptococcosis and aspergillosis. J Am Acad Dermatol 23 (1990) 602-607
5. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
6. Munoz P., Rodriguez C., Bouza E., et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant 4 (2004) 636-643
7. Dummer J.S., Lazariashvilli N., Barnes J., Ninan M., and Milstone A.P. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant 23 (2004) 1376-1381
8. Chiou C.C., Groll A.H., and Walsh T.J. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 5 (2000) 120-135
9. Kartsonis N.A., Saah A.J., Joy Lipka C., Taylor A.F., and Sable C.A. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 50 (2005) 196-205
10. Swatek F., Halde C., Rinaldi M.J., and Shadomy H.J. Aspergillus species and other opportunistic saprophytic hyaline hyphomycetes. In: Lennette E.H., Balows A., Hausler Jr. W.J., and Shadomy H.J. (Eds). Manual of clinical microbiology. 4th ed. (1985), American Society of Microbiology, Washington, DC 584
11. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 33 (2001) 1692-1696
12. Chandrasekar P.H., and Ito J.I. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 40 suppl 6 (2005) S392-S400 1
13. Rex J.H., and Walsh T.J. Estimatiing the true costs of amphotericin B. Clin infect Dis 29 (1999) 1408-1410
14. Kontoyiannis D.P., Hachem R., Lewis R.E., et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98 (2003) 292-299 15
15. Singhal P., Usuda K., and Mehta A.C. Post-lung transplantation Aspergillus niger infection. J Heart Lung Transplant 24 (2005) 1446-1447
16. Cancidas (caspofungin acetate) for injection (2004), Merck, White House Station, NJ. http://www.cancidas.com/caspofungin_acetate/cancidas/hcp/index.jsp Assessed 2003
17. Lin S.J., Schranz J., and Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32 (2001) 358-366
18. Stevens D.A., Kan V.L., Judson M.A., et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 30 (2000) 696-709
19. Denning D.W. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 23 (1996) 608-615
20. Trenschel R., Trampenaue C., Elmaagacil A., et al. Caspofungin after allogeneic stem cell transplantation: a single center experience of 16 patients treated for fever of unknown origin or invasive mycosis (2002) Presented at: 28th Annual Meeting of the European Group of Blood and Marrow Transplantation. Montreux, Switzerland, March 26.
21. Sable C., Nguyen B.-Y., Chodakewitz J.A., and DiNubile M.J. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. T. Transpl Infect Dis 4 (2002) 25-30
22. Singh N., Limaye A.P., Forrest G., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective multicenter observational study. Transplantation 81 (2006) 320-325
23. Shlobin O.A., Dropulic L.K., Orens J.B., Mcdyer J.F., Conte J.V., and Girgis R. Mediastinal mass due to aspergillus fumigatus after lung transplantation: a case report. J Heart Lung Transplant 24 (2005) 1991-1994
24. Kirkpatrick W.R., Perea S., Coco B.J., and Patterson T.F. Efficacy of caspofungin acetate with voriconazole in a guinea pig model for invasive aspergillosis. Antimicrob Agents Chemother 46 (2002) 2564-2568